Clinical Trials Browser

Ann Arbor Stage II Mantle Cell Lymphoma

Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma

Advanced Gastric Cancer

Endometrial Neoplasms

Thymic epithelial tumor, Mediastinal Neoplasms, Thymoma

Triple Negative Breast Neoplasms

Lymphoma, Large B-Cell, Diffuse

Breast Neoplasms

Multiple Myeloma, Triple Negative Breast Neoplasms

Sarcoma, Ewing, Osteosarcoma

Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Lymphoma, T-Cell

Dendritic Cell Sarcoma, Interdigitating

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Lymphoma, Large B-Cell, Diffuse

Dendritic Cell Sarcoma, Interdigitating

Carcinoma, Carcinoma, Pancreatic Ductal

Fallopian Tube Neoplasms, Ovarian Neoplasms

Thyroid Neoplasms

Enteropathy-Associated T-Cell Lymphoma

Lymphoma, Large B-Cell, Diffuse

Melanoma, Sarcoma

Lymphoma, Large B-Cell, Diffuse

Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Stomach Neoplasms

Stomach Neoplasms

Breast Neoplasms

Lymphoma, Large B-Cell, Diffuse

Triple Negative Breast Neoplasms

Clinical Trials

Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma

Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy

Evaluation of Pressurized Intraperitoneal Aerosol Chemotherapy With VRT106 Versus PIPAC in Patients With Advanced Gastric Cancer and PeritonealMetastasis: A Prospective, Multicenter, Open-Label, Randomized Controlled Trial

A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-Endometrial01)

6 vs 3 Cycles of Neoadjuvant Chemotherapy for Potentially Resectable Locally Advanced Thymic Epithelial Tumors

BEXAR

Cancer Immunotherapeutic (PCI) Strategy in Triple Negative Breast Cancer Patients

Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma

Telmisartan for Prevention of Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients

Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype

Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma

Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)

Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas

BOLD-100 Plus Doxorubicin in Advanced Soft Tissue Sarcomas

Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma

ALL Backbone in AYAs

A Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone（T-CHP） in Previously Untreated Patients With CD20-positive DLBCL

A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1

Using Tumor Models to Determine Treatments

JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer

Efficacy of Organoid-Based Chemotherapy Drug Precision Screening to Guide Treatment for Thyroid Cancer

GOAL

A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL

TQB2916 Injection Combined With Chemotherapy or Penpulimab Injection in the Treatment of Solid Tumors

Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL

QUEEN-Neo

KEYPARTNER

EPICURE

SPECTRA

Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study

First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOP

to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC)

Combination Therapy of Anthracyclines for Children With Nephroblastoma